REGULATORY

• MHLW Issues Q&A on Conditional Approval System
  May 1, 2026

• Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
  May 1, 2026

• METI Clarifies Naphtha Comments, Reaffirms Medical Priority
  April 30, 2026

• Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
  April 30, 2026

• Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
  April 30, 2026

• Health Insurance Reform Bill Sails Through Lower House
  April 30, 2026

• MOF Pushes for Full-Scale FY2027 Off-Year Drug Price Revision Ahead of “Spring” Proposal
  April 28, 2026

• Japan Panel Backs Boehringer’s IPF Drug, Moderna COVID Vaccine
  April 28, 2026

• Japan Allows Flexibility on Pharmacopoeia Test Differences in Supply Crunch
  April 28, 2026

• Zepbound in Line for OSA Approval after Key Panel Nod
  April 27, 2026

• LDP Team Urges Patent-Period Price Maintenance, CEA Review in Growth Strategy Proposal
  April 27, 2026

• Takaichi Says Govt to Weigh Response to MFN Drug Pricing Policy
  April 27, 2026

• Nitrosamines Found in Duloxetine, Diltiazem; Panel Sets Intake Limits
  April 27, 2026

• Health Insurance Reform Bill Clears Lower House Committee, Draws Backlash
  April 27, 2026

• Measles Cases Surge Past Last Year’s Total, Minister Vows Coordinated Response
  April 27, 2026

• JIHS Inks MOU with German Network to Boost Infectious Disease Preparedness
  April 27, 2026

• Govt Presents Draft Public-Private Investment Roadmap at Growth Strategy WG
  April 27, 2026

• H5N1 Pre-Pandemic Flu Vaccine Strain Re-Selected for FY2026 Stockpiling
  April 27, 2026

• War-Linked Supply Concerns Rise to 43 Cases, Focus Shifts to Solvents, Packaging
  April 24, 2026

• JPMA Pushes for “Freeze” on On-Patent Drug Price Cuts at LDP Meeting
  April 23, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »